HOUSTON / Mar 06, 2023 / Business Wire / U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (the "Company"), today announced that Carey Hendrickson, Chief Financial Officer, and Eric Williams, Chief Operating Officer, will participate in Oppenheimer 33rd Annual Healthcare Virtual Conference on Monday, March 13, 2023. The presentation will cover an overview of the Company.
A copy of USPh’s investor presentation is posted on the Company’s website at www.usph.com.
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. operates 645 outpatient physical therapy clinics in 40 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 36 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
Last Trade: | US$84.27 |
Daily Change: | -1.51 -1.76 |
Daily Volume: | 158,103 |
Market Cap: | US$1.280B |
August 06, 2025 August 01, 2025 April 30, 2025 March 03, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load